Can histology guide the use of targeted therapies?
Yes, histology can be instrumental in guiding the use of targeted therapies. Advances in molecular histology have enabled the identification of specific biomarkers and genetic mutations within tissues. For instance, the detection of HER2 overexpression in breast cancer tissues can lead to the use of HER2-targeted therapies like trastuzumab. Similarly, identifying EGFR mutations in lung cancer can guide the use of EGFR inhibitors. These targeted therapies can provide more effective and personalized treatment options.
